# Can digital brain twins dissolve the uncertainties surrounding unresponsive wakefulness?

**Authors:** Giuseppe Comerci, Stella Mosetti, Andrew J. Barnhart, Matthias Braun

PMC · DOI: 10.1186/s12910-026-01390-x · BMC Medical Ethics · 2026-01-30

## TL;DR

Digital brain twins may help diagnose and predict outcomes for unresponsive wakefulness syndrome but cannot resolve the moral dilemmas in end-of-life decisions.

## Contribution

The paper explores the ethical implications of using digital brain twins in managing unresponsive wakefulness syndrome.

## Key findings

- Digital brain twins can improve diagnostic accuracy and treatment predictions for UWS.
- Moral uncertainties in end-of-life decisions persist despite technological advancements.
- Ethical and psychological support is essential alongside technological tools for proxy decision-makers.

## Abstract

Unresponsive Wakefulness Syndrome (UWS), a condition characterized by wakefulness without awareness, presents significant medical and moral uncertainties, particularly in end-of-life decision-making. Digital Brain Twins (DBTs), virtual replicas of patients’ brains driven by advanced artificial intelligence, offer the potential to alleviate medical uncertainties by providing precise diagnoses, prognoses, and experimental platforms for treatment testing. This paper provides a theoretical contribution by examining the potential ethical impact of these technologies in the context of UWS. We argue that, while DBTs promise greater diagnostic accuracy, personalized predictions of recovery, and non-invasive tools for exploring therapeutic interventions, they do not necessarily resolve the moral uncertainties faced by proxy decision-makers. Decisions about withdrawing or continuing life-sustaining treatment are fundamentally moral and value-laden, often extending beyond empirical evidence provided by DBTs. Factors such as cognitive biases, emotional distress, and subjective interpretations of best interest further complicate these decisions. While DBTs represent a breakthrough in precision medicine, their role in navigating the ethical complexities of UWS is limited, emphasizing the need for integrated approaches that combine technological innovation with ethical and psychological support for proxies.

## Full-text entities

- **Genes:** DBT (dihydrolipoamide branched chain transacylase E2) [NCBI Gene 1629] {aka BCATE2, BCKAD-E2, BCKADE2, BCKDH-E2, BCOADC-E2, E2}
- **Diseases:** traumatic brain injury (MESH:D000070642), DBTs (MESH:D005330), Alzheimer's disease (MESH:D000544), mental disorders (MESH:D001523), Wakefulness Syndrome (MESH:D012893), pain (MESH:D010146), trauma (MESH:D014947), anoxia (MESH:D000860), locked-in syndrome (MESH:D000080422), UWS (MESH:C567934), anoxic brain injury (MESH:D002534), arrhythmias (MESH:D001145), ischemic heart disease (MESH:D017202), death (MESH:D003643), intellectual disabilities (MESH:D008607), brain stroke (MESH:D001927), Disorders of consciousness (MESH:D003244), neurological damage (MESH:D020196), brain damage (MESH:D001925), coma (MESH:D003128), cognitive disability (MESH:D003072)
- **Chemicals:** DBTs (-)
- **Species:** Malus domestica (apple, species) [taxon 3750], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12927249/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12927249/full.md

---
Source: https://tomesphere.com/paper/PMC12927249